3 completed, 3 recruiting, 2 unknown, 1 not yet recruiting. 8 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 3, Unknown 2, Not yet recruiting 1, Recruiting 1, Suspended 1 |
| Phase 1 | 2 | Recruiting 2 |
Follow Neuroendocrine Carcinomas: new trials by email Literature Review of Neuroendocrine Carcinomas trials Research Report on Neuroendocrine Carcinomas
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine Neoplasms CTX-471 - Neuroendocrine Neoplasm, Neuroendocrine Carcinomas | Phase 2 | Not yet recruiting | Compass Therapeutics | 58 | 2026-09-01 | 2026-07-06 |
| Neuroendocrine Carcinomas: Patient Journey And Treatment Outcomes In Latin America Observational study - Neuroendocrine Carcinomas, Lung Neuroendocrine Carcinoma | Recruiting | Latin American Cooperative Oncology Group | 200 | 2025-12-16 | 2026-09-08 | |
| A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer IDE849, durvalumab, IDE161 - Small-cell Lung Cancer, Neuroendocrine Carcinomas | Phase 1 / Phase 2 | Recruiting | IDEAYA Biosciences | 262 | 2025-10-14 | 2026-07-09 |
| A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors ADCT-701 - Neuroendocrine Carcinomas, Neuroendocrine Tumors | Phase 1 | Recruiting | National Cancer Institute (NCI) | 70 | 2024-06-17 | 2026-10-16 |
| A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers XmAb20717 - Microsatellite High Cancers, Peritoneal Mesothelioma | Phase 2 | Suspended | M.D. Anderson Cancer Center | 140 | 2022-08-05 | 2026-10-13 |
| Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer Folfiri-bevacizumab, Folfiri - Neuroendocrine Carcinomas | Phase 2 | Completed | Hospices Civils de Lyon | 153 | 2017-09-04 | 2025-09-03 |
| Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas Temozolomide - Neuroendocrine Carcinomas | Phase 2 | Completed | National Cancer Institute, Naples | 25 | 2017-01-29 | 2020-10-26 |
| Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin cisplatinum and everolimus - Neuroendocrine Carcinomas | Phase 2 | Unknown | The Netherlands Cancer Institute | 39 | 2016-03-30 | 2021-04-20 |
| Phase II Study to Evaluate the Efficacy and Safety of TLC388 for Differentiated Neuroendocrine Carcinomas Patients TLC 388 - Neuroendocrine Carcinomas | Phase 2 | Completed | National Health Research Institutes, Taiwan | 23 | 2015-07-04 | 2019-04-03 |
| Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tumors bevacizumab + octreotide LAR + capecitabine - Neuroendocrine Carcinomas | Phase 2 | Unknown | University of Turin, Italy | 42 | 2006-01-01 | 2010-09-16 |
Carcinoma, Neuroendocrine (10) · Neuroendocrine Tumors (3) · Small Cell Lung Carcinoma (2) · Adrenocortical Carcinoma (1) · Hodgkin Disease (1) · Mesothelioma, Malignant (1) · Neuroblastoma (1) · Paraganglioma (1) · Pheochromocytoma (1) · Uterine Cervical Neoplasms (1)
Adenocarcinoma (10) · Carcinoma (10) · Neoplasms (10) · Neoplasms by Histologic Type (10) · Neoplasms, Germ Cell and Embryonal (10) · Neoplasms, Glandular and Epithelial (10) · Neoplasms, Nerve Tissue (10) · Neuroectodermal Tumors (10) · Neuroendocrine Tumors (7) · Neoplasms by Site (3) · Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Lung Diseases (2) · Lung Neoplasms (2) · Respiratory Tract Diseases (2)
Bevacizumab (1) · Capecitabine (1) · Carboplatin (1) · Cisplatin (1) · Everolimus (1) · IFL protocol (1) · Observation (1) · TLC 388 (1) · Temozolomide (1) · durvalumab (1)
Compass Therapeutics (1) · Hospices Civils de Lyon (1) · IDEAYA Biosciences (1) · Latin American Cooperative Oncology Group (1) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · National Cancer Institute, Naples (1) · National Health Research Institutes, Taiwan (1) · The Netherlands Cancer Institute (1) · University of Turin, Italy (1)
United States (3) · Italy (2) · Argentina (1) · Brazil (1) · France (1) · Mexico (1) · Netherlands (1) · Peru (1) · Taiwan (1)
Alfredo Berruti, MD, PhD (1) · Arvind Nageshwara Dasaru, MD (1) · Cheng-Chung Wu, MS (1) · Chia-Jui Yen, MD., PhD (1) · Chiun Hsu, MD., PhD (1) · Hui-Jen Tsai, MD., PhD (1) · Jaydira Del Rivero, M.D. (1) · Jen-Shi Chen, MD (1) · M. Tesselaar, MD (1) · Ming-Huang Chen, MD., PhD (1) · Ta-Chih Liu, MD., PhD (1) · Yee Chao, MD., PhD (1) · Yen-Yang Chen, MD (1)
PMID 24628963, PMID 31852810, PMID 35251315, PMID 36739879, PMID 38615472, PMID 39416174, PMID 40595495
2016 (1)